The biology of solid tumors is strongly determined by the interactions of cancer cells with
their surrounding microenvironment. In this regard, pancreatic cancer (pancreatic ductal …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related
death and is one of the most difficult-to-treat cancers. Surgical resection and adjuvant …

Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is
characterized by poor treatment response and low survival time. The current clinical …

Pancreatic cancer is a lethal disease, with fewer than 7% of patients surviving beyond 5
years following diagnosis. Immune responses are known to influence tumour progression …

Pancreatic cancer remains a highly recalcitrant disease despite the development of systemic
chemotherapies. New treatment options are thus urgently required. Dense stromal …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor
immune microenvironment (TIME) formed by interactions among cancer cells, immune cells …

The tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) is non-
immunogenic, which consists of the stellate cells, fibroblasts, immune cells, extracellular …

Pancreatic ductal adenocarcinoma (PDAC) is composed of a minority of malignant cells
within a microenvironment of extracellular matrix, fibroblasts, endothelial cells, and immune …

Pancreatic ductal adenocarcinoma (PDA), the most frequent type of pancreatic cancer,
remains one of the most challenging problems for the biomedical and clinical fields, with …

Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide and is
predicted to become second in 2030 in industrialized countries if no therapeutic progress is …